| Addressing clinical trials: can the multidisciplinary Tumor Board improve participation? A study from an academic women's cancer program. | |
| | |
MedLine Citation:
|
PMID: 20042225 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: The Tumor Board (TB) allows for an interdisciplinary approach to cancer treatment designed to encourage evidence-based treatment. However, its role in facilitating clinical trial participation has not been reported. We aimed to determine whether a prospective TB is an effective strategy for trial recruitment and to identify steps within the TB process that facilitate discussion of trial eligibility and optimize accrual. METHODS: We conducted a retrospective cross-sectional analysis of women presented to Gynecologic Oncology TB between March and December 2008. Patient demographics, TB recommendations, and post-TB patient discussions were abstracted. These were compared to data derived from the Department of Oncology Research to determine research team awareness of eligible patients and confirm trial enrollment(s). Data analysis was completed with Chi-square test; risk ratios and confidence intervals were calculated as summary measures. RESULTS: We reviewed 1213 case presentations involving 916 women. Overall, 358 TB recommendations (30%) identified eligible patients, of which enrollment consisted of 87 (24%) trials (6% therapeutic trials and 18% non-therapeutic trials). Compared to other types of TB recommendations, those involving trials were discussed less frequently at post-TB patient visits (79% vs. 44%). Documentation of trial discussion at the post-TB visit was more likely to result in trial participation, versus solely relying on the research staff to communicate enrollment eligibility with the treating team (RR 2.5, p=0.006). CONCLUSIONS: Patients identified by the TB were 2.5-times as likely to enroll in a clinical trial, but trials were mentioned only 44% of the time. Interventions that facilitate trial discussions during post-TB meetings are needed to improve trial participation. |
| | |
Authors:
|
Lindsay Kuroki; Ashley Stuckey; Priya Hirway; Christina A Raker; Christina A Bandera; Paul A DiSilvestro; Cornelius O Granai; Robert D Legare; Bachir J Sakr; Don S Dizon |
Related Documents
:
|
22513965 - Antifibrinolytic therapy to reduce haemoptysis from any cause. 22295255 - Can classification tree analyses help improve decision making about treatments for depr... 22291465 - Treatment for primary hypothyroidism: current approaches and future possibilities. 8248655 - The value of randomization and control in clinical trials. 20141245 - Testing the continuum of delusional beliefs: an experimental study using virtual reality. 6732425 - Drug-responsive symptoms in melancholia. |
Publication Detail:
|
Type: Journal Article Date: 2009-12-29 |
Journal Detail:
|
Title: Gynecologic oncology Volume: 116 ISSN: 1095-6859 ISO Abbreviation: Gynecol. Oncol. Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-02-15 Completed Date: 2010-03-10 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0365304 Medline TA: Gynecol Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 295-300 Citation Subset: IM |
Affiliation:
|
Warren Alpert Medical School of Brown University, Providence, RI, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Clinical Trials as Topic / methods* Cross-Sectional Studies Female Genital Neoplasms, Female / therapy* Gynecology Humans Medical Oncology Middle Aged Patient Acceptance of Health Care Patient Selection* Retrospective Studies Young Adult |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Bone remodeling of the Homo heidelbergensis mandible; the Atapuerca-SH sample.
Next Document: Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian ca...